Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
51-100 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__175_A4,1 | Lung | Primary cancer | 3,135 | Tumor/Malignant | 40.7% | 0.93 | 0.26 |
| NSCLC_38242124__IMC__175_A4,10 | Lung | Primary cancer | 3,642 | Stromal | 27.5% | 0.85 | 0.42 |
| NSCLC_38242124__IMC__175_A4,11 | Lung | Primary cancer | 2,707 | Tumor/Malignant | 57.1% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__175_A4,12 | Lung | Primary cancer | 2,297 | Tumor/Malignant | 32.7% | 0.89 | 0.33 |
| NSCLC_38242124__IMC__175_A4,13 | Lung | Primary cancer | 5,499 | Stromal | 51.8% | 0.96 | 0.16 |
| NSCLC_38242124__IMC__175_A4,14 | Lung | Primary cancer | 2,772 | Tumor/Malignant | 36.4% | 0.94 | 0.19 |
| NSCLC_38242124__IMC__175_A4,15 | Lung | Primary cancer | 2,740 | Stromal | 44.1% | 0.87 | 0.37 |
| NSCLC_38242124__IMC__175_A4,16 | Lung | Primary cancer | 2,936 | Stromal | 30.6% | 0.92 | 0.22 |
| NSCLC_38242124__IMC__175_A4,17 | Lung | Primary cancer | 4,066 | Immune | 51.1% | 0.55 | 0.57 |
| NSCLC_38242124__IMC__175_A4,2 | Lung | Primary cancer | 1,512 | Tumor/Malignant | 42.5% | 0.93 | 0.26 |
| NSCLC_38242124__IMC__175_A4,3 | Lung | Primary cancer | 2,042 | Tumor/Malignant | 30.8% | 0.53 | 0.64 |
| NSCLC_38242124__IMC__175_A4,4 | Lung | Primary cancer | 2,380 | Stromal | 33.8% | 0.59 | 0.78 |
| NSCLC_38242124__IMC__175_A4,5 | Lung | Primary cancer | 1,974 | Tumor/Malignant | 60.2% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__175_A4,6 | Lung | Primary cancer | 2,673 | Tumor/Malignant | 65.9% | 0.99 | 0.06 |
| NSCLC_38242124__IMC__175_A4,7 | Lung | Primary cancer | 1,491 | Stromal | 34.6% | 0.37 | 0.98 |
| NSCLC_38242124__IMC__175_A4,8 | Lung | Primary cancer | 1,550 | Tumor/Malignant | 38.6% | 0.98 | 0.04 |
| NSCLC_38242124__IMC__175_A4,9 | Lung | Primary cancer | 3,457 | Stromal | 31.2% | 0.84 | 0.43 |
| NSCLC_38242124__IMC__175_A5,1 | Lung | Primary cancer | 4,373 | Tumor/Malignant | 37.8% | 0.75 | 0.54 |
| NSCLC_38242124__IMC__175_A5,10 | Lung | Primary cancer | 3,202 | Tumor/Malignant | 66.4% | 0.93 | 0.21 |
| NSCLC_38242124__IMC__175_A5,11 | Lung | Primary cancer | 2,764 | Tumor/Malignant | 64.1% | 0.98 | 0.05 |
| NSCLC_38242124__IMC__175_A5,12 | Lung | Primary cancer | 3,952 | Tumor/Malignant | 80.4% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__175_A5,13 | Lung | Primary cancer | 4,010 | Tumor/Malignant | 41.8% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__175_A5,14 | Lung | Primary cancer | 4,271 | Tumor/Malignant | 41.6% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__175_A5,15 | Lung | Primary cancer | 2,937 | Tumor/Malignant | 37.1% | 0.94 | 0.21 |
| NSCLC_38242124__IMC__175_A5,16 | Lung | Primary cancer | 3,132 | Stromal | 56.3% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__175_A5,17 | Lung | Primary cancer | 2,717 | Tumor/Malignant | 48.6% | 0.94 | 0.24 |
| NSCLC_38242124__IMC__175_A5,2 | Lung | Primary cancer | 1,924 | Tumor/Malignant | 63.8% | 1.00 | 0.03 |
| NSCLC_38242124__IMC__175_A5,3 | Lung | Primary cancer | 1,476 | Stromal | 36.1% | 0.47 | 0.81 |
| NSCLC_38242124__IMC__175_A5,4 | Lung | Primary cancer | 3,742 | Tumor/Malignant | 37.5% | 0.75 | 0.53 |
| NSCLC_38242124__IMC__175_A5,5 | Lung | Primary cancer | 3,255 | Tumor/Malignant | 55.9% | 0.95 | 0.18 |
| NSCLC_38242124__IMC__175_A5,6 | Lung | Primary cancer | 2,342 | Stromal | 36.1% | 0.91 | 0.30 |
| NSCLC_38242124__IMC__175_A5,7 | Lung | Primary cancer | 2,320 | Tumor/Malignant | 50.6% | 0.93 | 0.23 |
| NSCLC_38242124__IMC__175_A5,9 | Lung | Primary cancer | 3,778 | Tumor/Malignant | 36.2% | 0.75 | 0.57 |
| NSCLC_38242124__IMC__175_A6,1 | Lung | Primary cancer | 4,537 | Tumor/Malignant | 44.4% | 1.00 | 0.06 |
| NSCLC_38242124__IMC__175_A6,10 | Lung | Primary cancer | 2,854 | Tumor/Malignant | 61.5% | 0.94 | 0.19 |
| NSCLC_38242124__IMC__175_A6,11 | Lung | Primary cancer | 2,675 | Tumor/Malignant | 48.0% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__175_A6,12 | Lung | Primary cancer | 3,218 | Tumor/Malignant | 49.9% | 0.97 | 0.13 |
| NSCLC_38242124__IMC__175_A6,13 | Lung | Primary cancer | 2,913 | Tumor/Malignant | 40.4% | 0.95 | 0.17 |
| NSCLC_38242124__IMC__175_A6,14 | Lung | Primary cancer | 4,124 | Tumor/Malignant | 38.2% | 0.94 | 0.24 |
| NSCLC_38242124__IMC__175_A6,15 | Lung | Primary cancer | 3,501 | Tumor/Malignant | 31.6% | 0.95 | 0.16 |
| NSCLC_38242124__IMC__175_A6,16 | Lung | Primary cancer | 2,655 | Tumor/Malignant | 34.3% | 0.92 | 0.28 |
| NSCLC_38242124__IMC__175_A6,2 | Lung | Primary cancer | 1,655 | Tumor/Malignant | 73.7% | 0.98 | 0.10 |
| NSCLC_38242124__IMC__175_A6,3 | Lung | Primary cancer | 2,958 | Tumor/Malignant | 33.3% | 0.53 | 0.82 |
| NSCLC_38242124__IMC__175_A6,4 | Lung | Primary cancer | 3,632 | Tumor/Malignant | 39.7% | 0.88 | 0.36 |
| NSCLC_38242124__IMC__175_A6,5 | Lung | Primary cancer | 3,151 | Tumor/Malignant | 63.1% | 0.97 | 0.13 |
| NSCLC_38242124__IMC__175_A6,6 | Lung | Primary cancer | 3,540 | Tumor/Malignant | 29.5% | 0.91 | 0.35 |
| NSCLC_38242124__IMC__175_A6,7 | Lung | Primary cancer | 1,620 | Tumor/Malignant | 50.0% | 0.92 | 0.25 |
| NSCLC_38242124__IMC__175_A6,8 | Lung | Primary cancer | 2,924 | Stromal | 38.8% | 0.78 | 0.53 |
| NSCLC_38242124__IMC__175_A6,9 | Lung | Primary cancer | 3,563 | Stromal | 38.2% | 0.88 | 0.36 |
| NSCLC_38242124__IMC__175_A7,1 | Lung | Primary cancer | 3,312 | Immune | 32.0% | 0.53 | 0.78 |